Literature DB >> 21183782

A stimulating way to improve T cell responses to poxvirus-vectored vaccines.

Stuart N Isaacs1.   

Abstract

Vaccines remain one of the most cost-effective public health measures. Despite ongoing efforts, protective vaccines against cancer and many infectious diseases, including malaria, tuberculosis, and HIV/AIDS, are still not in hand. Most investigators believe that to succeed against these difficult targets, vaccines that generate potent T cell responses are needed. In this issue of the JCI, Salek-Ardakani et al. show how the relative virulence of a virus/vaccine vector affects the memory CD8+ T cells generated and how the response may be enhanced. The work has important implications for the development of future vaccines that aim to trigger CD8+ T cell responses.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21183782      PMCID: PMC3007171          DOI: 10.1172/JCI45726

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  16 in total

1.  Duration of antiviral immunity after smallpox vaccination.

Authors:  Erika Hammarlund; Matthew W Lewis; Scott G Hansen; Lisa I Strelow; Jay A Nelson; Gary J Sexton; Jon M Hanifin; Mark K Slifka
Journal:  Nat Med       Date:  2003-08-17       Impact factor: 53.440

2.  The TNFR family members OX40 and CD27 link viral virulence to protective T cell vaccines in mice.

Authors:  Shahram Salek-Ardakani; Rachel Flynn; Ramon Arens; Hideo Yagita; Geoffrey L Smith; Jannie Borst; Stephen P Schoenberger; Michael Croft
Journal:  J Clin Invest       Date:  2010-12-22       Impact factor: 14.808

3.  Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox.

Authors:  R J Jackson; A J Ramsay; C D Christensen; S Beaton; D F Hall; I A Ramshaw
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

4.  Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes.

Authors:  Nilu Goonetilleke; Stephen Moore; Len Dally; Nicola Winstone; Inese Cebere; Abdul Mahmoud; Susana Pinheiro; Geraldine Gillespie; Denise Brown; Vanessa Loach; Joanna Roberts; Ana Guimaraes-Walker; Peter Hayes; Kelley Loughran; Carole Smith; Jan De Bont; Carl Verlinde; Danii Vooijs; Claudia Schmidt; Mark Boaz; Jill Gilmour; Pat Fast; Lucy Dorrell; Tomas Hanke; Andrew J McMichael
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

5.  Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein.

Authors:  E L Cooney; A C Collier; P D Greenberg; R W Coombs; J Zarling; D E Arditti; M C Hoffman; S L Hu; L Corey
Journal:  Lancet       Date:  1991-03-09       Impact factor: 79.321

6.  Immunologic responses to vaccinia vaccines administered by different parenteral routes.

Authors:  D J McClain; S Harrison; C L Yeager; J Cruz; F A Ennis; P Gibbs; M S Wright; P L Summers; J D Arthur; J A Graham
Journal:  J Infect Dis       Date:  1997-04       Impact factor: 5.226

7.  Vaccinia virus: a selectable eukaryotic cloning and expression vector.

Authors:  M Mackett; G L Smith; B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1982-12       Impact factor: 11.205

8.  Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus.

Authors:  D Panicali; E Paoletti
Journal:  Proc Natl Acad Sci U S A       Date:  1982-08       Impact factor: 11.205

9.  Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes.

Authors:  J W Yewdell; J R Bennink; G L Smith; B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1985-03       Impact factor: 11.205

10.  A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans.

Authors:  Matilu Mwau; Inese Cebere; Julian Sutton; Priscilla Chikoti; Nicola Winstone; Edmund G-T Wee; Tara Beattie; Yun-Hsiang Chen; Lucy Dorrell; Helen McShane; Claudia Schmidt; Mary Brooks; Sandip Patel; Joanna Roberts; Christopher Conlon; Sarah L Rowland-Jones; Job J Bwayo; Andrew J McMichael; Tomáš Hanke
Journal:  J Gen Virol       Date:  2004-04       Impact factor: 3.891

View more
  1 in total

Review 1.  OX40:OX40L axis: emerging targets for improving poxvirus-based CD8(+) T-cell vaccines against respiratory viruses.

Authors:  John Goulding; Vikas Tahiliani; Shahram Salek-Ardakani
Journal:  Immunol Rev       Date:  2011-11       Impact factor: 12.988

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.